110 related articles for article (PubMed ID: 12847315)
1. Chemotherapy for neuroblastoma: is it all or none?
Maris JM; Castleberry RP
J Pediatr Hematol Oncol; 2003 Jul; 25(7):512-4. PubMed ID: 12847315
[No Abstract] [Full Text] [Related]
2. Ph+ALL in a pediatric patient with neuroblastoma in infancy.
Suenobu S; Handa YS; Kuga S; Kakiuchi T; Akiyoshi K; Imai K; Izumi T
Pediatr Int; 2010 Jun; 52(3):e147-9. PubMed ID: 20723114
[No Abstract] [Full Text] [Related]
3. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries.
Rich BS; McEvoy MP; Kelly NE; Oh E; Abramson SJ; Price AP; Cheung NK; La Quaglia MP
J Pediatr Surg; 2011 Jan; 46(1):103-7. PubMed ID: 21238649
[TBL] [Abstract][Full Text] [Related]
4. [Molecular biology markers of neuroblastoma as the basis for a therapy concept].
Girgert R; Treuner J; Schweizer P
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():1053-5. PubMed ID: 9101780
[TBL] [Abstract][Full Text] [Related]
5. The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) studies.
Castel V; García-Miguel P; Melero C; Navajas A; Navarro S; Molina J; Badal MD; Ruiz-Jimenez JI
Eur J Cancer; 1995; 31A(4):642-5. PubMed ID: 7576986
[TBL] [Abstract][Full Text] [Related]
6. [Past and future role of surgery in neuroblastoma].
Kaneko M
Nihon Geka Gakkai Zasshi; 2005 Jul; 106(7):418-21. PubMed ID: 16045184
[TBL] [Abstract][Full Text] [Related]
7. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
[TBL] [Abstract][Full Text] [Related]
8. [Metaiodobenzylguanidine scintigraphy in the diagnosis and followup of neuroblastoma. Apropos of 16 cases].
Hammami H; Hassine L; Mhiri A; Sellem A; Oubich F; Gharssallah L; Barsaoui S; Ben Brahim H
Tunis Med; 2007 May; 85(5):413-6. PubMed ID: 17657930
[TBL] [Abstract][Full Text] [Related]
9. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
10. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
11. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.
Donfrancesco A; De Bernardi B; Carli M; Mancini A; Nigro M; De Sio L; Casale F; Bagnulo S; Helson L; Deb G
Eur J Cancer; 1995; 31A(4):612-5. PubMed ID: 7576980
[TBL] [Abstract][Full Text] [Related]
12. Possible relationship of chromosome abnormalities and gene amplification with effects of chemotherapy: a neuroblastoma xenograft study.
Tsuchida Y; Kaneko Y; Kanda N; Makino S; Utakoji T; Saito S
Prog Clin Biol Res; 1985; 175():171-80. PubMed ID: 3991730
[TBL] [Abstract][Full Text] [Related]
13. Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion.
Ladenstein R; Pötschger U; Siabalis D; Garaventa A; Bergeron C; Lewis IJ; Stein J; Kohler J; Shaw PJ; Holter W; Pistoia V; Michon J
J Clin Oncol; 2011 Feb; 29(4):441-8. PubMed ID: 21149662
[TBL] [Abstract][Full Text] [Related]
14. Current status of molecular biology and treatment strategy for neuroblastoma.
Mugishima H
Int J Clin Oncol; 2012 Jun; 17(3):189. PubMed ID: 22588782
[No Abstract] [Full Text] [Related]
15. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
[TBL] [Abstract][Full Text] [Related]
16. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.
van Wezel EM; Zwijnenburg D; Zappeij-Kannegieter L; Bus E; van Noesel MM; Molenaar JJ; Versteeg R; Fiocco M; Caron HN; van der Schoot CE; Koster J; Tytgat GA
J Mol Diagn; 2015 Jan; 17(1):43-52. PubMed ID: 25445214
[TBL] [Abstract][Full Text] [Related]
17. Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation.
Pinto N; Cipkala DA; Ladd PE; Pu Y; Cohn SL
Pediatr Blood Cancer; 2014 Jun; 61(6):1104-6. PubMed ID: 24293072
[TBL] [Abstract][Full Text] [Related]
18. Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.
Harttrampf AC; Chen Q; Jüttner E; Geiger J; Vansant G; Khan J; Kontny U
BMC Res Notes; 2017 Aug; 10(1):413. PubMed ID: 28818093
[TBL] [Abstract][Full Text] [Related]
19. Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1.
Matsushita K; Uchida K; Saigusa S; Ide S; Hashimoto K; Koike Y; Otake K; Inoue M; Tanaka K; Kusunoki M
J Pediatr Surg; 2012 Jul; 47(7):1323-30. PubMed ID: 22813791
[TBL] [Abstract][Full Text] [Related]
20. The surgical challenge of neuroblastoma.
Kiely EM
J Pediatr Surg; 1994 Feb; 29(2):128-33. PubMed ID: 8176583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
